Onasemnogene abeparvovec for the treatment of spinal muscular atrophy

References

• Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–165.
   PubMed Web of Science ®Google Scholar
• Wirth B. Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci. 2021;44(4):306–322.
   PubMed Web of Science ®Google Scholar
• Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis. 2017;12(1):124.
   PubMedGoogle Scholar
• Lally C, Jones C, Farwell W, et al. Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States. Orphanet J Rare Dis. 2017;12(1):175.
   PubMedGoogle Scholar
• Strunk A, Abbes A, Stuitje AR, et al. Validation of a fast, robust, inexpensive, two-tiered neonatal screening test algorithm on dried blood spots for spinal muscular atrophy. Int J Neonatal Screen. 2019;5(2):21.
   PubMed Web of Science ®Google Scholar
• Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10(8):597–609.
   PubMed Web of Science ®Google Scholar
• Calucho M, Bernal S, Alías L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208–215.
   PubMed Web of Science ®Google Scholar
• Tiziano FD, Bertini E, Messina S, et al. The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscul Disord. 2007;17(5):400–403.
   PubMed Web of Science ®Google Scholar
• Schorling DC, Becker J, Pechmann A, et al. Discrepancy in redetermination of SMN2 copy numbers in children with SMA. Neurology. 2019;93(6):267–269.
   PubMed Web of Science ®Google Scholar
• Bladen CL, Thompson R, Jackson JM, et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J Neurol. 2014;261:152–163.
   PubMed Web of Science ®Google Scholar
• Butchbach MER. Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosc. 2016; 3:7.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3): 197–207.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103–115.
   PubMed Web of Science ®Google Scholar
• Wang CH, Finkel RS, Bertinin ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027–1049.
   PubMed Web of Science ®Google Scholar
• Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020;21(3):307–315.
   PubMed Web of Science ®Google Scholar
• De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842–856.
   PubMed Web of Science ®Google Scholar
• Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag. 2019;15:1153–1161.
   PubMed Web of Science ®Google Scholar
• Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38–43.
   PubMed Web of Science ®Google Scholar
• Slayter J, Hodgkinson V, Lounsberry J, et al. A Canadian adult spinal muscular atrophy outcome measures toolkit: results of a national consensus using a modified delphi method. J Neuromuscul Dis. 2021;8(4):579–588.
   PubMedGoogle Scholar
• Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7(2):97–100.
   PubMedGoogle Scholar
• Kichula EA, Proud CM, Farrar MA, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021;64(4):413–427.
   PubMed Web of Science ®Google Scholar
• Dangouloff T, Vrscaj E, Servais L, et al. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord. 2021;31(6):574–582.
   PubMed Web of Science ®Google Scholar
• Dangouloff T, Botty C, Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.
   PubMed Web of Science ®Google Scholar
• Hale K, Ojodu J, Singh S. Landscape of spinal muscular atrophy newborn screening in the United States: 2018–2021. Int J Neonatal Screen. 2021;7(3):33.
   PubMed Web of Science ®Google Scholar
• Kariyawasam DST, D’Silva AM, Vetsch J, et al. “We needed this”: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy. EClinicalMedicine. 2021;33:100742.
   PubMedGoogle Scholar
• Lopez-Chacon M, Buehner AN, Rao VK. Spinal muscular atrophy diagnosed by newborn screening. Pediatr Neurol Briefs. 2019;33:5.
   PubMedGoogle Scholar
• Lowes LP, Alfano LN, Arnold WD, et al. Impact of age and motor function in a phase 1/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39–45.
   PubMed Web of Science ®Google Scholar
• Dangouloff T, Burghes A, Tizzano EF, et al. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord. 2020;30(1):93–103.
   PubMed Web of Science ®Google Scholar
• Boardman FK, Sadler C, Young PJ. Newborn genetic screening for spinal muscular atrophy in the UK: the views of the general population. Mol Genet Genomic Med. 2018;6(1):99–108.
   PubMed Web of Science ®Google Scholar
• Novartis Gene Therapies. Novartis Gene Therapies recommits to Global Managed Access Program for 2021. Novartis. 2021 Jan 15. Available at: www.novartis.com/news/novartis-gene-therapies-recommits-global-managed-access-program-2021 [Last accessed 2021 Jan 15]
   Google Scholar
• Colella P, Ronzitti G, Mingozzie F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87–104.
   PubMed Web of Science ®Google Scholar
• Dayton RD, Wang DB, Klein RL. The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther. 2012;12(6):757–766.
   PubMed Web of Science ®Google Scholar
• Murlidharan G, Sakamoto K, Rao L, et al. CNS-restricted transduction and CRISPR/Cas9-mediated gene deletion with an engineered AAV vector. Mol Ther Nucleic Acids. 2016;5:e338.
   PubMedGoogle Scholar
• Rashnonejad A, Chermahini GA, Li S, et al. Large-scale production of adeno-associated viral vector serotype-9 carrying the human survival motor neuron gene. Mol Biotechnol. 2016;58(1):30–36.
   PubMed Web of Science ®Google Scholar
• Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286(5448):2244–2245.
   PubMed Web of Science ®Google Scholar
• Thomsen G, Burghes AHM, Hsieh C, et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat Med. 2021;27(10):1701–1711.
   PubMed Web of Science ®Google Scholar
• Dalwadi DA, Calabria A, Tiyaboonchai A, et al. AAV integration in human hepatocytes. Mol Ther. 2021;29(10):2898–2909.
   PubMed Web of Science ®Google Scholar
• Domenger C, Grimm D. Next-generation AAV vectors—do not judge a virus (only) by its cover. Hum Mol Genet. 2019;28(R1):R3–R14.
   PubMed Web of Science ®Google Scholar
• Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–378
   PubMed Web of Science ®Google Scholar
• Ronzitti G, Gross D-A, Mingozzi F. Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol. 2020;11:670.
   PubMed Web of Science ®Google Scholar
• Chu WS, Ng J. Immunomodulation in administration of rAAV: preclinical and clinical adjuvant pharmacotherapies. Front Immunol. 2021;12:658038.
   PubMed Web of Science ®Google Scholar
• Calcedo R, Morizono H, Wang L, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol. 2011;18(9):1586–1588.
   PubMed Web of Science ®Google Scholar
• Day JW, Finkel RS, Mercuri E, et al. Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Mol Ther Methods Clin Dev. 2021;21:76–82.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Azadeh M, Buchlis G, et al. Evaluation of the humoral response to adeno-associated virus-based gene therapy modalities using total antibody assays. AAPS J. 2021;23(6):108.
   PubMed Web of Science ®Google Scholar
• Saraiva J, Nobre RJ, Almeida LP. Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV. J Control Release. 2016;241:94–109.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29(2):464–488.
   PubMed Web of Science ®Google Scholar
• Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–293.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017 ;377: 1713–1722.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834–841.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Muntoni F, Baranello F, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832–841
   PubMed Web of Science ®Google Scholar
• McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8(16):1248–1254.
   PubMed Web of Science ®Google Scholar
• Kotulska K, Fattal-Valevski A, Haberlova J. Recombinant adeno-associated virus serotype 9 gene therapy in spinal muscular atrophy. Front Neurol. 2021;12:726468.
   PubMed Web of Science ®Google Scholar
• Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74(3):540–566.
   Web of Science ®Google Scholar
• Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16(6):1073–1080.
   PubMed Web of Science ®Google Scholar
• ZOLGENSMA. Prescribing Information. Novartis; October 2021. Available at: www.novartis.us/sites/www.novartis.us/files/zolgensma.pdf [Last accessed 2021 Nov 8]
   Google Scholar
• Weiβ C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6(1): 17–27.
   PubMedGoogle Scholar
• Mercuri E, Lucibello S, Perulli M, et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis. 2020;15(1):84.
   PubMed Web of Science ®Google Scholar
• Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810–817.
   PubMed Web of Science ®Google Scholar
• Kolb SJ, Coffey CS, Yankey JW, et al., Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883–891.
   PubMed Web of Science ®Google Scholar
• Al-Zaidy SA, Kolb SJ, Lowes L, et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis. 2019;6(3):307–317.
   PubMedGoogle Scholar
• Strauss K, Farrar M, Muntoni F, et al. OPR-201 Onasemnogene abeparvovec for presymptomatic infants with spinal muscular atrophy and 2 copies of SMN2: a phase III study. Eur J Neurol. 2021;28(Suppl 1):S950–S951.
   Google Scholar
• Strauss KA, Muntoni F, Farrar MA, et al. Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy: final results of SPR1NT study for children with three copies of SMN2. Neurology.2022;In press:Vol. 98.
   Google Scholar
• SPR1NT: an open-label, single-arm clinical trial of presymptomatic patients with SMA. Novartis Gene Therapies, Inc., 2021. Available at: www.zolgensma-hcp.com/clinical-experiences/spr1nt-trial-efficacy. [Last accessed 2021 Nov 5]
   Google Scholar
• De Onis M. WHO child growth standards based on length/height, weight and age. Acta Paediatr. 2006;450:76–85.
   Google Scholar
• Finkel RS, Day JW, De Vivo DC, et al. RESTORE: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy - rationale and study design. J Neuromuscul Dis. 2020;7(2):145–152.
   PubMedGoogle Scholar
• Servais L, De Vivo DC, Kirschner J, et al. Outcomes in US spinal muscular atrophy patients identified by newborn screening or clinical diagnosis: findings from the RESTORE registry. Neurology.2022;In press:Vol. 98.
   Google Scholar
• Servais L, De Vivo DC, Kirschner J, et al. Effectiveness and safety of onasemnogene abeparvovec in older patients with spinal muscular atrophy: real-world outcomes from the RESTORE registry. Neurology.2022;In press:Vol. 98.
   Google Scholar
• Registry of patients with a diagnosis of spinal muscular atrophy (SMA). ClinicalTrials.gov identifier: NCT04174157. 2019 Nov 22. Available at: clinicaltrials.gov/ct2/show/NCT04174157?term=NCT04174157&draw=2&rank=1 [Last accessed 2021 Nov 5]
   Google Scholar
• Wei Y, McCormick A, MacKenzie A, et al. The Canadian Neuromuscular Disease Registry: connecting patients to national and international research opportunities. Paediatr Child Health. 2018;23(1):20–26.
   PubMed Web of Science ®Google Scholar
• Hodgkinson VL, Oskoui M, Lounsberry J, et al. A national spinal muscular atrophy registry for real-world evidence. Can J Neurol Sci. 2020;47(6):810–815.
   PubMed Web of Science ®Google Scholar
• Hodgkinson-Brechenmacher V, Oskoui M, Brais B, et al. SMA – OUTCOME MEASURES AND REGISTRIES. EP.262. The Canadian Neuromuscular Disease Registry: a national spinal muscular atrophy (SMA) registry for real-world evidence. Neuromuscul Disord. 2021;31(Supplement 1):S129.
   Google Scholar
• Pechmann A, Konig K, Bernert G, et al. SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis. 2019;14(1):18.
   PubMed Web of Science ®Google Scholar
• Friese J, Geitmann S, Holzwarth D, et al. Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec –a single centre experience. J Neuromuscul Dis. 2021;8(2):209–216.
   PubMedGoogle Scholar
• Waldrop MA, Karingada C, Storey MA, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020;146(3):e20200729.
   PubMed Web of Science ®Google Scholar
• Feldman AG, Parsons JA, Dutmer CM, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225:252–258.
   PubMed Web of Science ®Google Scholar
• Shieh PB, Bonnemann CG, Muller-Felber W, et al. Re: “Moving forward after two deaths in a gene therapy trial of myotubular myopathy” by Wilson and Flotte. Hum Gene Ther. 2020;31(15–16):787.
   PubMed Web of Science ®Google Scholar
• Wilson JM, Flotte TR. Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Hum Gene Ther. 2020;31(13–14):695–696.
   PubMed Web of Science ®Google Scholar
• D‘Amico A, Longo A, Fattori F, et al. Hepatobiliary disease in XLMTM: a common comorbidity with potential impact on treatment strategies. Orphanet J Rare Dis. 2021;16(1):425.
   PubMed Web of Science ®Google Scholar
• Philippidis A. Fourth boy dies in clinical trial of astellas‘ AT132. Hum Gene Ther. 2021;32(19–20):1008.
   PubMedGoogle Scholar
• Perez BA, Shutterly A, Chan YK, et al. Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020;10(2):119.
   PubMed Web of Science ®Google Scholar
• Childers MK, Joubert R, Poulard K, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med. 2014;6(220):220ra10.
   PubMed Web of Science ®Google Scholar
• Morales L, Gambhir Y, Bennett J, et al. Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV. Mol Ther. 2020;28(8):1753–1755.
   PubMed Web of Science ®Google Scholar
• Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2021;231:265–268.
   PubMed Web of Science ®Google Scholar
• Day JW, Mendell JR, Mercuri E, et al. Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug Saf. 2021;44:1109–1119.
   PubMed Web of Science ®Google Scholar
• D’Silva AM, Holland S, Kariyawasam D, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9(3):339–350.
   PubMed Web of Science ®Google Scholar
• Bonnemann CG. AAV related immunological safety and toxicity: preliminary clinical observations in the GAN and MTM1 trials. Presented at: Virtual Workshop on Systemic Immunogenicity Considerations of AAV-Mediated Gene Therapy, NIH, NCATS; 2020. Available at: videocast.nih.gov/watch=38547 [Last accessed 2021 Nov 8].
   Google Scholar
• Mueller C, Berry JD, McKenna-Yasek DM, et al. SOD1 Suppression with adeno-associated virus and MicroRNA in familial ALS. N Engl J Med. 2020;383(2):151–158.
   PubMed Web of Science ®Google Scholar
• Van Alstyne M, Tattoli I, Delestree N, et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24(7):930–940.
   PubMed Web of Science ®Google Scholar
• Crawford TO, Sumner CJ. Assuring long-term safety of highly effective gene-modulating therapeutics for rare diseases. J Clin Invest. 2021;131(15):e152817.
   PubMed Web of Science ®Google Scholar
• Huang L, Wan J, Wu Y, et al. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Life Sci. 2021;270:119142.
   PubMed Web of Science ®Google Scholar
• Duan D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther. 2018;26(10):2337–2356.
   PubMed Web of Science ®Google Scholar
• Ramos J, Chamberlain JS. Gene therapy for duchenne muscular dystrophy. Expert Opin Orphan Drugs. 2015;3(11):1255–1266.
   PubMed Web of Science ®Google Scholar
• Philippidis A. After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial. Hum Gene Ther. 2022;33(3–4):111–115.
   Google Scholar
• Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin Immunity in Duchenne’s Muscular Dystrophy. N Engl J Med. 2010;363(15):1429–1437.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the safety and tolerability of PF-06939926 gene therapy in Duchenne Muscular Dystrophy. ClinicalTrials.gov identifier: NCT03362502. 2021 Oct 15. Available at: clinicaltrials.gov/ct2/show/NCT03362502. [Last accessed 2021 Dec 13]
   Google Scholar
• Landfeldt E, Pechmann A, McMillan HJ, et al. Costs of illness of spinal muscular atrophy: a systematic review. Appl Health Econ Health Policy. 2021;19(4):501–520.
   PubMed Web of Science ®Google Scholar
• McMillan HJ, Gerber B, Cowling T, et al. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553–568.
   PubMedGoogle Scholar
• Belter L, Cruz R, Kulas S, et al. Economic burden of spinal muscular atrophy: an analysis of claims data. J Mark Access Health Policy. 2020;8(1):1843277.
   PubMedGoogle Scholar
• Garrison LP, Jiao B, Dabbous O. Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies. J Manag Care Spec Pharm. 2021;27(5):674–681
   PubMed Web of Science ®Google Scholar
• Dean R, Jensen I, Cyr P, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the institute for clinical and effectiveness review (ICER). J Mark Access Health Policy. 2021;9:1889841.
   PubMedGoogle Scholar
• Harris E. Potential solutions to current pricing models for cell and gene therapies. Horsham, PA: Life Science Leader, 2019 Oct 1. Available at: www.lifescienceleader.com/doc/potential-solutions-to-current-pricing-models-for-cell-and-gene-therapies-0001 [Last accessed 2021 Nov 5]
   Google Scholar
• Seymore B. Payment models for pricey transformative pharmaceuticals. PharmacyTimes.com. Updated 2020 Feb 4. Available at: https://www.pharmacytimes.com/view/payment-models-for-pricey-transformative-pharmaceuticals. [Last accessed 2021 Nov 5]
   Google Scholar
• Wong CH, Li D, Wang N, et al. Estimating the financial impact of gene therapy. medRxiv. Available at: www.medrxiv.org/content/10.1101/2020.10.27.20220871v1.full [ Last accessed 2021 Nov 8]
   Google Scholar
• Aballéa S, Thokagevistk K, Velikanova R, et al. Health economic evaluation of gene replacement therapies: methodological issues and recommendations. J Mark Access Health Policy. 2020;8:1822666.
   PubMedGoogle Scholar
• Broekhoff TF, Sweegers CCG, Krijkamp EM, et al. Early cost-effectiveness of onasemnogene abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health. 2021;24:759–769.
   PubMed Web of Science ®Google Scholar
• Jena AB, Lakdawalla DN. Value frameworks for rare diseases: should they be different? Washington, DC: Health Affairs Blog, 2017 Apr 12. Available at: www.healthaffairs.org/do/10.1377/hblog20170412.059563/full/ [Last accessed 2021 Apr 12].
   Google Scholar
• Ollendorf DA, Chapman RH, Pearson SD. Evaluating and valuing drugs for rare conditions: no easy answers. Value Health. 2018;21:547–552.
   PubMed Web of Science ®Google Scholar
• Shih STF, Farrar M, Wiley V, et al. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry. 2021;92(12):1296–1304.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of intravenous OAV101 (AVXS-101) in pediatric patients with spinal muscular atrophy (SMA) (SMART). clinicalTrials.gov identifier: NCT04851873. 2021 Apr 21. Available at: clinicaltrials.gov/ct2/show/NCT04851873 [Last accessed 2021 Nov 5]
   Google Scholar
• Study of intrathecal administration of onasemnogene abeparvovec-xioi for spinal muscular atrophy (STRONG). ClinicalTrials.gov identifier: NCT03381729. 2021 June 9. Available at: https://clinicaltrials.gov/ct2/show/NCT03381729?term=NCT03381729 [Last accessed 2021 Nov 18]
   Google Scholar
• Finkel RS, Day JW, Darras BT, et al. One-time administration of AVXS-101 IT for spinal muscular atrophy: phase I/II study (STRONG). Presented online at the 16th International Child Neurology Congress/49th International Child Neurology Society 2020 Virtual Annual Meeting; 2020 Oct 12–20.
   Google Scholar
• Efficacy and safety of intrathecal OAV101 (AVXS-101) in pediatric patients with type 2 spinal muscular atrophy (SMA) (STEER). ClinicalTrials.gov identifier: NCT05089656. 2021 Oct 22. Available at: clinicaltrials.gov/ct2/show/NCT05089656. [Last accessed 2021 Nov 5]
   Google Scholar
• Harada Y, Rao VK, Arya K, et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020;62(4):550–554.
   PubMed Web of Science ®Google Scholar
• Kray KM, McGovern VL, Chugh D, et al. Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice. Neurobiol Dis. 2021;159:105488.
   PubMed Web of Science ®Google Scholar
• Pagliarini V, Guerra M, Di Rosa V, et al. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in spinal muscular atrophy cells. J Neurochem. 2020;153:264–275.
   PubMed Web of Science ®Google Scholar
• Poletti A, Fischbeck KH. Combinatorial treatment for spinal muscular atrophy: an editorial for ‘Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in spinal muscular atrophy cells‘ on page 264. J Neurochem. 2020;153(2):146–149.
   PubMed Web of Science ®Google Scholar
• A study of nusinersen among participants with spinal muscular atrophy who received onasemnogene abeparvovec (RESPOND). ClinicalTrials.gov identifier: NCT04488133. 2021 Sept 29. Available at: www.clinicaltrials.gov/ct2/show/NCT04488133 [Last accessed 2021 Oct 20]
   Google Scholar
• Masson R, Brusa C, Scoto M, et al. Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review. Dev Med Child Neurol. 2021;63(5):527–536.
   PubMed Web of Science ®Google Scholar
• Nance ME, Shi R, Hakim CH, et al. AAV9 edits muscle stem cells in normal and dystrophic adult mice. Mol Ther. 2019;27(9):1568–1585.
   PubMed Web of Science ®Google Scholar
• Fischell JM, Fishman PS. A multifaceted approach to optimizing AAV delivery to the brain for the treatment of neurodegenerative diseases. Front Neurosci. 2021;15:747726.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhu M, Zhang Y, et al. Crossing the blood-brain barrier with AAV vectors. Metab Brain Dis. 2021;36(1):45–52.
   PubMed Web of Science ®Google Scholar
• Nonnenmacher M, Wang W, Child MA, et al. Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning. Mol Ther. 2021;20:366–378.
   Web of Science ®Google Scholar
• Marsic D, Mendez-Gomez HR, Zolotukhin S. High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing. Mol Ther Methods Clin Dev. 2015;2:15041.
   PubMed Web of Science ®Google Scholar
• Weinmann J, Weis S, Sippel J, et al. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nature. 2020;11:5432.
   Web of Science ®Google Scholar
• Tabebordbar M, Lagerborg KA, Stanton A, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184(19):4919–38.e22.
   PubMed Web of Science ®Google Scholar
• Kariyawasam DST, Russell JS, Wiley V, et al. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med. 2020;22(3):557–565.
   PubMed Web of Science ®Google Scholar
• D‘Silva AM, Kariyawasam DST, Best S, et al. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. Dev Med Child Neurol. 2022;64(5):625–632.
   PubMed Web of Science ®Google Scholar
• Hanlon KS, Kleinstiver BP, Garcia SP, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun. 2019;10:4439.
   PubMed Web of Science ®Google Scholar
• Yu W, Wu Z. Use of AAV vectors for CRISPR-mediated in vivo genome editing in the retina. Methods Mol Biol. 2019;1950:123–139.
   PubMedGoogle Scholar
• Li JJ, Lin X, Tang C, et al. Disruption of splicing-regulatory elements using CRISPR/Cas9 to rescue spinal muscular atrophy in human iPSCs and mice. Natl Sci Rev. 2020;7:92–101.
   PubMed Web of Science ®Google Scholar
• Zhou M, Hu Z, Qiu L, et al. Seamless genetic conversion of SMN2 to SMN1 via CRISPR/Cpf1 and single-stranded oligodeoxynucleotides in spinal muscular atrophy patient-specific induced pluripotent stem cells. Hum Gene Ther. 2018;29:1252–1263.
   PubMed Web of Science ®Google Scholar
• Waddington SN, Privolizzi R, Karda R, et al. A broad overview and review of CRISPR-Cas technology and stem cells. Curr Stem Cell Rep. 2016;2:9–20.
   PubMedGoogle Scholar
• Xu Y, Li Z. CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J. 2020;18:2401–2415.
   PubMed Web of Science ®Google Scholar
• Khalaf K, Janowicz K, Dyszkiewicz-Konwinska M, et al. CRISPR/Cas9 in cancer immunotherapy: animal models and human clinical trials. Genes (Basel). 2020;11:921.
   PubMed Web of Science ®Google Scholar
• Hirakawa MP, Krishnakumar R, Timlin JA, et al. Gene editing and CRISPR in the clinic: current and future perspectives. Biosci Rep. 2020;40(4):BSR20200127.
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/results?cond=&term=crispr&cntry=&state=&city=&dist= [Last accessed 2022 Mar 10]
   Google Scholar
• Kariyawasam DST, D’Silva A, Lin C, et al. Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy. Front Neurol. 2019;10:898
   PubMed Web of Science ®Google Scholar
• Servais L, Baranello G, Scoto M, et al. Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opin Investig Drugs. 2021;30(5):519–527.
   PubMed Web of Science ®Google Scholar